Effects of Neuromuscular Electrical Stimulation Combined With Ultrasound on Stroke Patients With Sarcopenia
A Randomized Controlled Trial of Neuromuscular Electrical Stimulation Combined With Therapeutic Ultrasound on Muscle Mass, Muscle Strength, and Physical Function in Stroke Patients With Sarcopenia.
The goal of this clinical trial is to learn if combining neuromuscular electrical stimulation (NMES) with therapeutic ultrasound (UT) can improve muscle mass, muscle strength, and physical function in stroke patients with sarcopenia.
The main questions it aims to answer are:
Does combined NMES and UT therapy increase muscle mass and strength more than conventional rehabilitation alone?
Does the combined therapy improve physical function (balance, gait, and activities of daily living) better than either therapy alone?
Researchers will compare four groups:
Conventional rehabilitation only (control group)
Conventional rehabilitation plus UT
Conventional rehabilitation plus NMES
Conventional rehabilitation plus combined UT and NMES
Participants will:
Receive 4 weeks of rehabilitation therapy, 6 days per week
Undergo assessments of muscle mass (via ultrasound), muscle strength (handgrip, isokinetic testing), and physical function (Fugl-Meyer, FIM, balance, and gait tests) before and after the 4-week intervention
Receive either UT (1 MHz, 0.5-0.8 W/cm², 20 min/session, 2 sessions/day), NMES (50 Hz, 300μs pulse width, 20 min/session, 2 sessions/day), both, or standard care only
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Background: Stroke is a leading cause of disability worldwide. Sarcopenia, characterized by loss of muscle mass and function, is a common complication after stroke, with a prevalence of approximately 46.7% within the first six months. Post-stroke sarcopenia significantly impairs patients' ability to walk independently, maintain balance, and perform daily activities. Current interventions primarily include exercise, physical therapy, and nutritional support, but these approaches have limitations, particularly for elderly patients who cannot tolerate vigorous exercise due to comorbidities or disability.
Therapeutic ultrasound (UT) is a non-invasive, safe, and cost-effective modality that promotes tissue regeneration and muscle repair through mechanical vibration and increased growth factor secretion. Neuromuscular electrical stimulation (NMES) induces involuntary muscle contraction, preventing disuse atrophy, preserving muscle thickness, and promoting protein synthesis. However, no study has systematically compared UT and NMES, or their combination, specifically in stroke-related sarcopenia.
Objective: This study aims to (1) compare the efficacy of UT versus NMES in improving muscle mass, strength, and physical function in stroke patients with sarcopenia; (2) evaluate whether combined UT and NMES therapy produces synergistic effects superior to either monotherapy; and (3) explore the potential mechanisms of action.
Study Design: This is a prospective, single-center, randomized, single-blind controlled trial. Eligible participants will be randomly assigned in a 1:1:1:1 ratio to one of four groups: (1) conventional rehabilitation alone (control), (2) UT + conventional rehabilitation, (3) NMES + conventional rehabilitation, or (4) combined UT + NMES + conventional rehabilitation. The intervention period is 4 weeks, with assessments performed at baseline and immediately after the intervention.
Sample Size: Based on prior literature (α = 0.05, 1-β = 0.80, effect size = 0.25), accounting for a 10% dropout rate, the total sample size is 152 participants (approximately 38 per group).
Interventions:
Conventional rehabilitation: Exercise therapy (30 min) and occupational therapy (30 min), twice daily, 6 days/week for 4 weeks.
UT group: In addition to conventional rehabilitation, UT (1 MHz, 0.5-0.8 W/cm², 20 min, 2 sessions/day, 6 days/week) applied to the affected wrist extensors and quadriceps.
NMES group: In addition to conventional rehabilitation, NMES (50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 min, 2 sessions/day, 6 days/week) applied to the same muscle groups.
Combined group: Both UT and NMES in addition to conventional rehabilitation.
Outcome Measures:
Primary outcomes: Muscle mass (muscle thickness via musculoskeletal ultrasound), muscle strength (handgrip strength, isokinetic torque), and physical function (Fugl-Meyer Assessment, Functional Independence Measure, modified Rankin Scale, balance, and gait tests).
Secondary outcomes: Surface electromyography (RMS and iEMG), Hamilton Depression Scale, and safety/adverse event monitoring.
Statistical Analysis: Data will be analyzed using SPSS 26.0. Intention-to-treat analysis will be applied. Between-group comparisons will use one-way ANOVA with post-hoc tests (LSD/Bonferroni), within-group changes will use paired t-tests, and correlation analyses will explore relationships between muscle mass improvement and functional recovery.
Ethics and Dissemination: The study has been approved by the Ethics Committee of Nanjing First Hospital (Approval Number: KY20250425-12). All participants will provide written informed consent. Results will be disseminated through peer-reviewed publications and conference presentations.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 2100061
- Nanjing First Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Diagnosis of first-ever stroke confirmed by CT or MRI, with stable vital signs, disease course between 3 weeks and 6 months.
Diagnosis of sarcopenia according to the 2019 Asian Working Group for Sarcopenia (AWGS) criteria: reduced handgrip strength (male < 28 kg, female < 18 kg) and/or gait speed < 1.0 m/s, and reduced appendicular skeletal muscle mass index (male < 7.0 kg/m², female < 5.4 kg/m²).
Age between 30 and 75 years.
Brunnstrom stage of affected upper and lower limbs ≥ III, and modified Ashworth scale ≤ 2.
No significant consciousness or cognitive impairment.
Willing and able to provide written informed consent.
Exclusion Criteria:
- Presence of significant emotional or cognitive impairment.
Obesity or overweight (body mass index > 25 kg/m²).
Unable to stand up from a chair with or without assistance.
Comorbidities including renal, hepatic, or heart failure.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Conventional Rehabilitation Only
Participants receive conventional rehabilitation therapy only, including exercise therapy and occupational therapy, 2 sessions per day, 6 days per week for 4 weeks.
|
|
|
Experimental: Ultrasound Therapy Plus Conventional Rehabilitation
Participants receive conventional rehabilitation therapy plus therapeutic ultrasound (UT) applied to the affected wrist extensors and quadriceps (1 MHz, 0.5-0.8
W/cm², 20 min/session, 2 sessions/day, 6 days/week) for 4 weeks.
|
Ultrasound therapy delivered at 1 MHz, 0.5-0.8
W/cm², 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the PHYSIOSON-EXPERT device.
Applied to the affected wrist extensors and quadriceps.
|
|
Experimental: Neuromuscular Electrical Stimulation Plus Conventional Rehabilitation
Participants receive conventional rehabilitation therapy plus neuromuscular electrical stimulation (NMES) applied to the affected wrist extensors and quadriceps (50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 min/session, 2 sessions/day, 6 days/week) for 4 weeks.
|
Neuromuscular electrical stimulation delivered at 50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the LGT-2320D device.
Applied to the affected wrist extensors and quadriceps.
|
|
Experimental: Combined UT and NMES Plus Conventional Rehabilitation
Participants receive conventional rehabilitation therapy plus both therapeutic ultrasound (UT) and neuromuscular electrical stimulation (NMES) applied to the affected wrist extensors and quadriceps, using the same parameters as the single-therapy groups, for 4 weeks.
|
Ultrasound therapy delivered at 1 MHz, 0.5-0.8
W/cm², 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the PHYSIOSON-EXPERT device.
Applied to the affected wrist extensors and quadriceps.
Neuromuscular electrical stimulation delivered at 50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the LGT-2320D device.
Applied to the affected wrist extensors and quadriceps.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Quadriceps Muscle Thickness on the Affected Side
Prazo: Baseline and 4 weeks
|
Quadriceps muscle thickness on the affected (paretic) side will be measured using B-mode musculoskeletal ultrasound with a high-frequency linear probe.
Muscle thickness includes the thickness of the rectus femoris and vastus intermedius.
Measurements will be taken with the participant in the supine position with hips and knees extended.
|
Baseline and 4 weeks
|
|
Change in Handgrip Strength
Prazo: Baseline and 4 weeks
|
Handgrip strength will be measured using a hand dynamometer on the unaffected side.
Participants will be asked to squeeze the dynamometer with maximum effort for 3 seconds, and the average of three measurements will be recorded.
|
Baseline and 4 weeks
|
|
Change in Fugl-Meyer Assessment Score
Prazo: Baseline and 4 weeks
|
The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index.
It is scored on a 3-point ordinal scale (0=cannot perform, 1=partially performs, 2=performs fully).
Total score ranges from 0 to 100, with higher scores indicating better motor function.
|
Baseline and 4 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Functional Independence Measure (FIM) Score
Prazo: Baseline and 4 weeks
|
The Functional Independence Measure (FIM) assesses functional independence across 18 items covering motor and cognitive domains.
Each item is scored from 1 (total assistance required) to 7 (complete independence).
Total score ranges from 18 to 126, with higher scores indicating greater independence in daily activities.
|
Baseline and 4 weeks
|
|
Change in Modified Rankin Scale (mRS) Score
Prazo: Baseline and 4 weeks
|
The modified Rankin Scale (mRS) measures the degree of disability or dependence in daily activities of participants who have had a stroke.
Scores range from 0 (no symptoms) to 6 (death).
Lower scores indicate better functional outcomes and greater independence.
|
Baseline and 4 weeks
|
|
Change in Hamilton Depression Scale (HAMD) Score
Prazo: Baseline and 4 weeks
|
The Hamilton Depression Scale (HAMD) assesses depressive symptoms across 17 items, including depressed mood, guilt, and insomnia.
Total scores range from 0 to 42, with higher scores indicating more severe depression.
|
Baseline and 4 weeks
|
|
Change in Gait Speed
Prazo: Baseline and 4 weeks
|
Gait speed will be measured using the Gait and Balance Evaluation System during the 10-meter walk test.
Participants will walk at their usual pace, and the average of three trials will be recorded in meters per second.
|
Baseline and 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Manifestações Neuromusculares
- Condições Patológicas, Anatômicas
- Atrofia Muscular
- Atrofia
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Derrame
- Sarcopenia
- Terapêutica
- Diatermia
- Hipertermia, induzida
- Terapia ultrassônica
Outros números de identificação do estudo
- KY20250425-12
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .